Search

DRC: First MDA campaign in Loa-LF co-endemic areas

CNTD provides support to endemic countries to administer regular treatment at large scale against lymphatic filariasis (LF) for populations at risk through annual rounds of preventive chemotherapy (PCT) with Ivermectin (IVM) and albendazole (ALB). 

 

In DRC, Bas Congo (Kongo Central) is endemic for Onchocerciasis, Lymphatic Filariasis, Schistosomiasis and Geo-helminthiasis.  LF can be eliminated by the mass distribution of Ivermectin and Albendazole but the presence of the parasite Loa loa-complicates the treatment of Onchocerciasis and Lymphatic Filariasis with Ivermectin due to the severe adverse effects that happen in patients with Loa Microfilaremia.

In July 2015, CNTD supported the treatment of 9 Loa-LF co-endemic areas in Kongo Central province with Albendazole only, the first ever mass treatment conducted using the new WHO protocol for co-endemic areas of treatment with Albendazole only, twice a year. The total amount invested in the treatment has been $81,037 at $0.10 per person treated. 

Loa-LF co-endemic districts in Kongo Central province treated with Albendazole

Zone de Sante

Total population

Target

Boma

204167

163334

Boma Bungu

85960

68768

Kitona

98373

78698

Kizu

67213

53770

Kuimba

101653

81322

Muanda

143486

114789

Nzanza

147056

117645

Tshela

96539

77231

Vaku

77000

61600

 Total

1021447

817157

       

To validate the accuracy of reported coverage, verification should be performed in all areas where the medication was administered, this to ensure that corrective action is taken quickly where it is discovered that coverage is suboptimal.

CNTD completed the first verification coverage survey in DRC using the LQAS method to verify the coverage target.  A second survey has taken place in 2016 after the successful third round of medication administered to all 9 districts. All districts passed the target of 80% and the provincial coverage increased from 67% in the first survey to 85% in the second.